Kern Pharma Highlighted P-IV Study Results of CT-P13 (biosimilar, infliximab) for Rheumatic Disease
- The P-IV open-label, multicenter study evaluating CT-P13 in 30 adult patients with rheumatic disease incl. PsA, RA, and AS across 10 study centers in Thailand. CT-P13 was administered via 2h IV infusions at doses approved for use in Thailand (3mg/kg for RA; 5mg/kg for AS and PsA)
- The results showed that the therapy was found to be well tolerated and effective across indications, acc. to a study published in Future Medicine, disease activity improved by 16wk. was maintained through the end of the treatment period, 2 patients discontinued treatment with CT-P13 during the study period
- No cases of malignancy, drug-induced liver disease, or tuberculosis during the treatment and follow-up periods were observed
Ref: HCP Live | Image: Kern Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.